Emcure Pharmaceuticals Limited (BOM:544210)

Market Cap	313.33B +68.8%
Revenue (ttm)	88.50B +17.2%
Net Income	8.70B +43.2%
EPS	45.90 +39.7%
Shares Out	n/a
PE Ratio	36.02
Forward PE	28.58
Dividend	3.00 (0.18%)
Ex-Dividend Date	Aug 14, 2025

Volume	69,170
Average Volume	37,554
Open	1,585.20
Previous Close	1,593.85
Day's Range	1,574.70 - 1,672.65
52-Week Range	890.00 - 1,653.60
Beta	n/a
RSI	66.24
Earnings Date	May 22, 2026

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the develop...

• Industry: Pharmaceutical Preparations
• Founded: 1981
• Employees: 6,731
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544210

Financial Performance

In fiscal year 2025, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.